Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2019

View Archived Issues

Identification of a novel target for the development of stroke treatments

Hitgen, Sun Pharma Advanced Research enter DEL-based drug discovery collaboration

Gene editing alleviates AD deficits in mouse models

China's NMPA clears HDAC6 inhibitor CS-3003 for phase I trials

Runx2 as a new target in chronic rhinosinusitis with neo-osteogenesis

AAV delivery of EPO-R76E delays retinal degeneration in a mouse model of geographic atrophy

Discovery of the first selective inhibitor of group XVI phospholipase A2

ACAM is a potential molecular target for treating multiple sclerosis

Identification of pyrrolidine amide derivatives as novel N-acylethanolamine acid amidase inhibitors

Results on safety, tolerability and pharmacokinetics of benapenem in healthy volunteers

Discovery of a druggable mechanism underlying tumorigenesis in ovarian cancer

RGC-32 as new target in chronic multiple sclerosis

Apelin receptor agonists identified at Bristol-Myers Squibb

Amgen presents new Mcl-1 inhibitors

Identification of a biomarker of inflammatory bowel disease severity

Wee1-like protein kinase inhibitors patented by Shanghai De Novo Pharmatech

Selection Bioscience discloses androgen receptor antagonists

Development of a novel, selective, kappa-opioid receptor antagonist

JS Innopharm patents ERK-2 inhibitors

AbbVie initiates phase I study of alpha-synuclein-targeting antibody ABBV-0805 for Parkinson's

Kyowa Hakko Kirin begins phase I study of KHK-4323 for atopic dermatitis

LRP-1 targeting confers retinal neuroprotection in diabetic mice

Phase III VELOS-2 trial explores use of HL-036 in patients with dry eye

BrainStorm initiates phase II study of MSC-NTF cells in progressive MS

Biohaven initiates phase III trial of troriluzole for spinocerebellar ataxia

Infinity and Roche enter master clinical supply agreement for MARIO-3 combination trial of IPI-549

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...